Third shot of COVID-19 vaccine: Pfizer to seek US authorization

Summary

  • Researchers are investigating the third dose of the COVID-19 vaccine to provide better protection against the emerging variants of the coronavirus.
  • Pfizer disclosed that the Company would seek US authorization for a third dose of its COVID-19 vaccine.
  • The ongoing trial demonstrated that a third dose could boost the antibody levels 5-10 times higher against the new strains.
  • In another news, AbbVie, Biogen, and Pfizer collaborated to produce the world’s largest browsable resource linking rare protein-coding genetic variants.

Research from several nations indicates the COVID-19 vaccine developed by Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX), and other widely used COVID-19 vaccines, offer strong protection against the highly contagious delta variant. This strain is spreading rapidly worldwide and now accounts for most new infections in the US.

New York-headquartered Pfizer is about to pursue US authorization for a third dose of its COVID-19 vaccine. On 8 July 2021, the Company highlighted that another shot within 12 months could considerably boost immunity and possibly help to invade the latest more contagious variant of novel coronavirus.

Copyright © 2020 Kalkine Media

ALSO READ: COVID-19: Are Intranasal vaccines better than the traditional vaccine shots?

Pfizer-BioNTech COVID-19 vaccine may require 3rd dose

Two doses of most COVID-19 vaccines are essential for developing high levels of antibodies against all variants of the coronavirus, not only the delta variant.

The ongoing clinical trial, conducted for the Pfizer-BioNTech COVID-19 vaccine, has demonstrated that a third dose can boost the antibody levels 5-10 times higher against the new variants of the coronavirus as compared to the first two doses alone.

MUST READ: COVID-19 vaccine booster shots: do we really need them?

As per the interim data from an ongoing trial, the third COVID-19 shot is also anticipated to provide better protection against the Beta variant, first identified in South Africa, and the Delta variant, identified in India.  Besides, Pfizer plans to apply for emergency authorization of a third dose for its COVID-19 vaccine to the Food and Drug Administration (FDA).

As mentioned by several media reports, in laboratory tests, blood from several dozen people given the first dose of Pfizer or AstraZeneca Plc (LON:AZN) COVID-19 vaccines hardly showed inhibition against the delta strain. But after some weeks of getting their second dose, the boost in immunity was demonstrated, and scientists highlighted that it was strong enough for neutralizing delta variant.

© Skypixel | Megapixl.com

Pfizer COVID-19 vaccine supply to arrive a month earlier in AU

Australia's supply of the COVID-19 vaccines developed by Pfizer has been brought forward, with almost 4.5 million doses, expected to reach in September earlier, now anticipated to be available in August. The earlier arrival of the September doses could help immunize more people against COVID-19 during the year.

Australia has between 300,000 and 350,000 doses of Pfizer per week to administer, but demand surpasses that. But Pfizer has confirmed that from 19 July, Australia can anticipate 1 million doses of its vaccine a week and the government anticipates getting 4.5 million dose deliveries in August.

Australian Prime Minister Scott Morrison expects that every Australian will be offered a vaccine by the end of 2021.

Collaboration between Abbvie, Biogen and Pfizer

On 8 July 2021, AbbVie (NYSE:ABBV), Biogen Inc. (NASDAQ:BIIB) and Pfizer collaborated to form the world’s biggest browsable resource connecting rare protein-coding genetic variants to human health and disease. The browser is managed by the Broad Institute of MIT and Harvard and gives access to results from analyses of whole-exome sequencing data from 300,000 UK Biobank research participants.

Copyright © 2020 Kalkine Media

The partnership between Pfizer, Biogen, and AbbVie makes this information available underscores the significance of working together for advancement. Consistent with members' collaboration commitment, these findings can now be accessed via the new browser without any charge. Furthermore, this browser will enable researchers worldwide to explore and utilize the data for their areas of interest following UK Biobank’s terms of use.

ALSO READ: Silver lining: COVID-19 scares Australia’s criminals out of their jobs

Comment


Disclaimer